250 related articles for article (PubMed ID: 16553045)
1. [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
Huisman AM; Jacobs JW; Buttgereit F; Bijlsma JW
Ned Tijdschr Geneeskd; 2006 Mar; 150(9):476-80. PubMed ID: 16553045
[TBL] [Abstract][Full Text] [Related]
2. [New developments in glucocorticoid therapy: selective glucocorticoid receptor agonists, nitrosteroids and liposomal glucocorticoids].
Spijker AJ
Ned Tijdschr Geneeskd; 2006 May; 150(21):1205; author reply 1205. PubMed ID: 16768287
[No Abstract] [Full Text] [Related]
3. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.
Stahn C; Löwenberg M; Hommes DW; Buttgereit F
Mol Cell Endocrinol; 2007 Sep; 275(1-2):71-8. PubMed ID: 17630118
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands.
Löwenberg M; Stahn C; Hommes DW; Buttgereit F
Steroids; 2008 Oct; 73(9-10):1025-9. PubMed ID: 18221974
[TBL] [Abstract][Full Text] [Related]
5. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
Schäcke H; Berger M; Rehwinkel H; Asadullah K
Mol Cell Endocrinol; 2007 Sep; 275(1-2):109-17. PubMed ID: 17630119
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice.
Kleiman A; Tuckermann JP
Mol Cell Endocrinol; 2007 Sep; 275(1-2):98-108. PubMed ID: 17587493
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects.
Schäcke H; Schottelius A; Döcke WD; Strehlke P; Jaroch S; Schmees N; Rehwinkel H; Hennekes H; Asadullah K
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):227-32. PubMed ID: 14694204
[TBL] [Abstract][Full Text] [Related]
8. Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index.
Schäcke H; Rehwinkel H; Asadullah K
Curr Opin Investig Drugs; 2005 May; 6(5):503-7. PubMed ID: 15912964
[TBL] [Abstract][Full Text] [Related]
9. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?
Newton R; Holden NS
Mol Pharmacol; 2007 Oct; 72(4):799-809. PubMed ID: 17622575
[TBL] [Abstract][Full Text] [Related]
10. Drug insight: selective agonists and antagonists of the glucocorticoid receptor.
McMaster A; Ray DW
Nat Clin Pract Endocrinol Metab; 2008 Feb; 4(2):91-101. PubMed ID: 18212811
[TBL] [Abstract][Full Text] [Related]
11. Nitric oxide up-regulates the glucocorticoid receptor and blunts the inflammatory reaction in porcine endotoxin sepsis.
Da J; Chen L; Hedenstierna G
Crit Care Med; 2007 Jan; 35(1):26-32. PubMed ID: 17095945
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory functions of glucocorticoid-induced genes.
Clark AR
Mol Cell Endocrinol; 2007 Sep; 275(1-2):79-97. PubMed ID: 17561338
[TBL] [Abstract][Full Text] [Related]
13. [Current insights into the development of new glucocorticoid receptor ligands].
Buttgereit F; Song IH; Straub RH; Burmester GR
Z Rheumatol; 2005 Apr; 64(3):170-6. PubMed ID: 15868334
[TBL] [Abstract][Full Text] [Related]
14. Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.
Schäcke H; Rehwinkel H; Asadullah K; Cato AC
Exp Dermatol; 2006 Aug; 15(8):565-73. PubMed ID: 16842594
[TBL] [Abstract][Full Text] [Related]
15. Optimised glucocorticoid therapy: the sharpening of an old spear.
Buttgereit F; Burmester GR; Lipworth BJ
Lancet; 2005 Feb 26-Mar 4; 365(9461):801-3. PubMed ID: 15733723
[TBL] [Abstract][Full Text] [Related]
16. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs.
Rhen T; Cidlowski JA
N Engl J Med; 2005 Oct; 353(16):1711-23. PubMed ID: 16236742
[No Abstract] [Full Text] [Related]
17. Non-genomic glucocorticoid effects to provide the basis for new drug developments.
Song IH; Buttgereit F
Mol Cell Endocrinol; 2006 Feb; 246(1-2):142-6. PubMed ID: 16388891
[TBL] [Abstract][Full Text] [Related]
18. Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects.
McMaster A; Ray DW
Exp Physiol; 2007 Mar; 92(2):299-309. PubMed ID: 17138619
[TBL] [Abstract][Full Text] [Related]
19. New glucocorticoids on the horizon: repress, don't activate!
Song IH; Gold R; Straub RH; Burmester GR; Buttgereit F
J Rheumatol; 2005 Jul; 32(7):1199-1207. PubMed ID: 16041872
[TBL] [Abstract][Full Text] [Related]
20. Minimizing the side effects of glucocorticoid therapy.
Baxter JD
Adv Intern Med; 1990; 35():173-93. PubMed ID: 2405592
[No Abstract] [Full Text] [Related]
[Next] [New Search]
